Similarly, allogenic MSC therapy in SLE patients induced increased levels of CD4+FOXP3 cells among PBMCs at one week, three months, and six months after IV infusion, which correlated with amelioration in disease activity [19]. The gene discussed is FOXP3; the disease is systemic lupus erythematosus.